A research team searches for every gene that helps tumors evade immunotherapy
Broad Institute
OCTOBER 11, 2023
As a first step, Manguso set his sights on treatments called PD-1 checkpoint inhibitors, which at the time had shown tremendous promise in clinical trials and would receive their first FDA approval in 2014. The findings suggest a complex, context-dependent relationship between IFNγ signaling and the anti-tumor immune response.
Let's personalize your content